Otoferlin Gene-Mediated Hearing Loss – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Hearing loss is a common congenital sensory disorder, affecting 1 in 500 newborns with bilateral hearing impairment. Around 50% to 60% of these cases have a genetic cause, with 80% attributed to autosomal recessive hearing loss. The OTOF gene, which encodes otoferlin, is a prominent contributor to non-syndromic recessive sensorineural hearing loss. OTOF-related deafness has two distinct forms: prelingual non-syndromic auditory neuropathy spectrum disorder (ANSD) and temperature-sensitive auditory neuropathy spectrum disorder (TS-ANSD). OTOF-related ANSD is characterized by severe-to-profound bilateral deafness from birth without inner-ear anomalies visible on MRI or CT scans of the temporal bones. Otoacoustic emissions (OAEs) are present, but auditory brain stem response is abnormal at birth. Newborn hearing screenings relying on OAEs alone may miss this condition in most cases, as OAEs can decrease or disappear with age in 20%-80% of individuals. TS-ANSD typically presents with mild to moderate hearing loss (0-55 dB) at normal body temperature. However, an increase in body temperature (approximately 0.5°C or more) can trigger sudden and severe-to-profound bilateral hearing loss, which usually resolves within hours of returning to baseline body temperature.

·       The prevalence of OTOF pathogenic variants in individuals with congenital autosomal recessive non-syndromic deafness varies depending on their ethnic background.

 

Thelansis’s “Otoferlin Gene-Mediated Hearing Loss Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Otoferlin Gene-Mediated Hearing Loss treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Otoferlin Gene-Mediated Hearing Loss across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Otoferlin Gene-Mediated Hearing Loss Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Otoferlin Gene-Mediated Hearing Loss – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Otoferlin Gene-Mediated Hearing Loss, Otoferlin Gene-Mediated Hearing Loss market outlook, Otoferlin Gene-Mediated Hearing Loss competitive landscape, Otoferlin Gene-Mediated Hearing Loss market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)